On May 28, Veracyte reported a 21% revenue growth in its Q1 2026 results. Non-GAAP gross margins expanded to 76%. Following strong cash generation, the company raised its 2026 guidance.
The biotech firm is pursuing strategic acquisitions to achieve financial self-sufficiency, aiming to add $100 million in combined annual revenue.
Read the full storyIntrinsic value analysis suggests Revvity is trading at $96.79, approximately $22.77 below its estimated fair value of $119.56.
AutoZone reported robust fiscal Q3 sales growth, driven by commercial market share gains and an accelerated expansion of its store footprint.